Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
338 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (92)
  • (-) Currently Recruiting (9)
  • Closed (83)

Medical Condition

  • Show all (338)
  • Addiction (4)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (2)
  • Blood Disorders (2)
  • Bone & Muscle (2)
  • Cancer (93)
    • (-) Bladder Cancer (2)
    • Brain Cancer (9)
    • Breast Cancer (9)
    • Gastrointestinal (2)
    • Gynecologic Cancer (6)
    • Kidney Cancer (1)
    • (-) Leukemia (7)
    • Liver Cancer (2)
    • Lung Cancer (4)
    • Lymphoma (9)
    • Multiple Myeloma (6)
    • Pancreatic Cancer (7)
    • Prostate Cancer (5)
  • COVID-19 (Coronavirus) (8)
  • Diabetes (6)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (1)
  • Gastrointestinal and Digestive Diseases (6)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (47)
  • Heart Disease (23)
  • Infectious Disease (11)
  • Liver Disease (13)
  • Lung Disease (2)
  • Neurological Disorders (46)
  • Obesity (7)
  • Obstetrics & Gynecology (12)
  • Pediatrics (22)
  • Psychiatric Disorders (4)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
  • Vascular Conditions (1)
Displaying 1 - 9 of 9

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (LOXO-LNC-24001)

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Read More

NeoSTOP-IT: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is for patients with a localized bladder cancer called muscle-invasive bladder cancer. Muscle-invasive bladder cancer is usually treated with a combination of chemotherapy and surgery. This surgery removes the entire bladder, which changes how they urinate for the rest of their life. Some patients will have a small opening in the…
Read More

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias (Children and Young Adults)

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is…
Read More

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that…
Read More

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML

Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Read More

Study of BLU-263 in Patients with Indolent Systemic Mastocytosis (ISM) or Monoclonal Mast Cell Activation Syndrome (mMCAS)

Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you,…
Read More

Study of Polatuzumab Vedotin in Combination with Chemotherapy in Subjectswith Richter's Transformation

Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Currently Recruiting
This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone,…
Read More

Study of SEA-CD70 in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drugs, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer are testing to see if SEA-CD70 is safe for people, and its side effects…
Read More

Study of TSC 100 & TSC 101 in Patients with Leukemia Undergoing Haploidentical Allogeneic Blood Stem Cell Transplantation (HCT)

Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The study involves research of two study drugs (TSC 100 and TSC 101), given in combination with the standard of care (SOC). The purpose of the study is to see if TSC 100 and TSC 101 are safe and effective in treating your blood cancer. The study also is measuring the effect of these study drugs on your immune system (immunogenicity of study drugs). TSC 100…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science